The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen.

Abstract:

BACKGROUND:Our aim was to study the efficacy and safety of combination chemotherapy with gemcitabine plus cisplatin (GC) for patients with advanced urothelial carcinoma (UC) after failure of methotrexate, vinblastin, adriamycin, and cisplatin (M-VAC) chemotherapy. METHODS:We studied a total of 33 patients with advanced UC. All patients were treated with M-VAC with a mean of 3.2 courses per patient and had showed disease progression or no response. Clinical and pathological features were correlated to survival rates, and the incidence and degree of toxicities were also retrospectively reviewed. RESULTS:A total of 132 courses of GC with a mean of 4.0 courses per patients were undergone. Two (6.0%) complete responses and 11 (33.3%) partial responses produced an overall response rate of 39.4%. In 55 assessable lesions, there were 2 (4%) complete responses, 13 (23%) partial responses, 31 (55%) with stable disease, and 10 (18%) with progressive disease. Overall, mean of survival time after GC chemotherapy was 10.5 months (range, 3.0-22.9 months). In univariate analysis, the patients with higher serum hemoglobin or single metastasis or no liver metastasis tended to survive longer than those with lower hemoglobin or multiple metastases or existence of liver metastasis. Although grade 3-4 neutropenia was seen in 22 patients (66.7%) and grade 3-4 thrombocytopenia was seen in 10 patients (30.3%), fatal side effects were not observed. CONCLUSIONS:The combination chemotherapy with GC seems feasible with no severe side effects and may provide a survival benefit for patients with advanced UC after failure of M-VAC chemotherapy.

journal_name

Int J Clin Oncol

authors

Gondo T,Ohori M,Hamada R,Tanaka A,Satake N,Takeuchi H,Nakashima J,Hatano T,Tachibana M

doi

10.1007/s10147-011-0188-4

subject

Has Abstract

pub_date

2011-08-01 00:00:00

pages

345-51

issue

4

eissn

1341-9625

issn

1437-7772

journal_volume

16

pub_type

临床试验,杂志文章
  • The evolving role of aromatase inhibitors in breast cancer.

    abstract::Anti-aromatase agents inhibit the cytochrome p-450 component of the aromatase enzyme complex responsible for the final step of estrogen biosynthesis in peripheral tissues. These drugs can be classified into first-generation (e.g., aminoglutethimide), second-generation (e.g., formestane and fadrazole), and third-genera...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s101470200040

    authors: Mokbel K

    更新日期:2002-10-01 00:00:00

  • International pediatric liver cancer pathological classification: current trend.

    abstract::This review describes the pathological classification of pediatric liver cancer types and subtypes proposed at the recent international symposium (March 2011, Los Angeles, USA) and meetings involving pathologists serving as central reviewers for the Children's Oncology Group, Société Internationale d'Oncologie Pédiatr...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s10147-013-0624-8

    authors: Tanaka Y,Inoue T,Horie H

    更新日期:2013-12-01 00:00:00

  • Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases.

    abstract:BACKGROUND:Cyclin E and p27 play pivotal roles in cancer development and progression. We investigated whether the prognosis in cases of non-small cell lung cancer without lymph node metastases that underwent complete resection could be associated with tissue expression of cyclin E, p27, and Ki-67. METHODS:Tumors from ...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s101470200053

    authors: Takahashi S,Kamata Y,Tamo W,Koyanagi M,Hatanaka R,Yamada Y,Tsushima T,Takaya S,Fukuda I

    更新日期:2002-12-01 00:00:00

  • A survival analysis using physique-adjusted tumor size of non-small cell lung cancer.

    abstract:BACKGROUND:Differences in individual body sizes have not been well considered when analyzing the survival of patients with non-small cell lung cancer (NSCLC). We hypothesized that physique-adjusted tumor size is superior to actual tumor size in predicting the prognosis. METHODS:Eight hundred and forty-two patients who...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-017-1219-6

    authors: Ozeki N,Fukui T,Kawaguchi K,Nakamura S,Hakiri S,Kato T,Hirakawa A,Yokoi K

    更新日期:2018-04-01 00:00:00

  • Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer.

    abstract:BACKGROUND:Constipation is a common side effect of opioid therapy. An observational study of opioid-induced constipation (OIC) in Japanese patients with cancer (OIC-J) included 212 patients with various tumor types. This post hoc analysis of OIC-J evaluated a subgroup of patients with gastrointestinal (GI) cancer. MET...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-020-01790-y

    authors: Harada T,Imai H,Fumita S,Noriyuki T,Gamoh M,Okamoto M,Akashi Y,Kizawa Y,Tokoro A

    更新日期:2021-01-01 00:00:00

  • Serum HER2 levels determined by two methods in patients with metastatic breast cancer.

    abstract:BACKGROUND:The role and the optimal measurement method of serum HER2 levels are not defined in patients with metastatic breast cancer (MBC). We prospectively assessed the prognostic value of serum HER2 levels in MBC using two methods, enzyme immunoassay (EIA) and chemiluminescence immunoassay (CLIA). METHODS:We collec...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-011-0253-z

    authors: Hayashi N,Nakamura S,Tokuda Y,Yagata H,Yoshida A,Ota H,Hortobagyi GN,Cristofanilli M,Ueno NT

    更新日期:2012-02-01 00:00:00

  • Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.

    abstract:BACKGROUND:To determine the indications for post-chemotherapy consolidative surgery in patients with clinical lymph node (LN) metastatic (cN+) urothelial carcinoma (UC). METHODS:Sixty UC patients with measurable cN+ but without detectable systemic visceral/bone dissemination received induction platinum-based chemother...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-015-0839-y

    authors: Urakami S,Yuasa T,Yamamoto S,Sakura M,Tanaka H,Hayashi T,Uehara S,Inoue Y,Fujii Y,Masuda H,Fukui I,Yonese J

    更新日期:2015-12-01 00:00:00

  • Trends in oncological CT imaging: clinical application of multidetector-row CT and 3D-CT imaging.

    abstract::Computed tomography (CT) plays an essential role in oncological imaging as the modality of screening for malignancies, mapping out the treatment strategy at staging, assessing response to the treatment, and following up patient outcome after the treatment. The advent of multidetector-row CT (MDCT) has brought about dr...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s10147-006-0586-1

    authors: Ueda T,Mori K,Minami M,Motoori K,Ito H

    更新日期:2006-08-01 00:00:00

  • Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.

    abstract:BACKGROUND:Phase I study of weekly administration of low-dose docetaxel/cisplatin concurrent with conventionally fractionated radiotherapy for locally advanced head and neck squamous cell carcinoma suggested the recommended dose of docetaxel at 10 mg/m2 and cisplatin at 20 mg/m2. Phase II study of the concurrent chemor...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-016-0997-6

    authors: Nakahara S,Takenaka Y,Ogawa K,Nishiike S,Yamamoto Y,Seo Y,Isohashi F,Suzuki O,Yoshioka Y,Sumida I,Yoshii T,Tomiyama Y,Inohara H

    更新日期:2016-12-01 00:00:00

  • Gastrectomy for invasive micropapillary carcinoma is associated with poorer disease-free and disease-specific survival.

    abstract:BACKGROUND:Invasive micropapillary carcinoma (IMPC) is a relatively rare subtype of gastric adenocarcinoma and has aggressive histopathologic characteristics, including lymphatic and vascular invasion. However, the associated long-term survival outcomes remain unclear. This study aimed to compare the clinicopathologica...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-019-01514-x

    authors: Kano M,Hihara J,Kaneko M,Uemura K,Ohge H,Sueda T

    更新日期:2019-12-01 00:00:00

  • Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.

    abstract:BACKGROUND:Irinotecan plus intravenous 5-fluorouracil with leucovorin is effective against gastrointestinal cancer. S-1 is an oral fluoropyrimidine derivative combining tegafur with the modulators 5-chloro-2,4-dihydroxypyrimidine (a potent dihydropyrimidine dehydrogenase inhibitor), and potassium oxonate (an orotate ph...

    journal_title:International journal of clinical oncology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10147-003-0359-z

    authors: Yamada Y,Yasui H,Goto A,Arai T,Ura T,Hamaguchi T,Muro K,Shimada Y,Shirao K

    更新日期:2003-12-01 00:00:00

  • Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer.

    abstract:BACKGROUND:UFT is composed of tegafur, a prodrug of 5-fluorouracil, and uracil, at a fixed ratio of 1: 4. UFT is widely used with leucovorin as adjuvant chemotherapy in patients with colon cancer. As reported, UFT/leucovorin should not be taken simultaneously with food because a high fat content will reduce the systemi...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10147-009-0919-y

    authors: Furuhata T,Meguro M,Nishidate T,Okita K,Ishiyama G,Iwayama Y,Hosokawa Y,Tsuruma T,Kimura Y,Mizuguchi T,Sasaki K

    更新日期:2009-12-01 00:00:00

  • Adenoid cystic carcinoma of the uterine cervix.

    abstract::Adenoid cystic carcinoma of the uterine cervix is a rare and peculiar variant of adenocarcinoma. This tumor represents 3% of all primary cervical adenocarcinomas, and it is locally aggressive and capable of metastasis to other organs even in its early stage. We report a case of adenoid cystic carcinoma stage IIIb that...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-004-0466-5

    authors: Nishida M,Nasu K,Takai N,Miyakawa I,Kashima K

    更新日期:2005-06-01 00:00:00

  • Aggressive angiomyxoma mimicking inguinal hernia in a man.

    abstract::We report the case of a 37-year-old Japanese man who presented with a left lower abdominal mass that was initially interpreted clinically as an inguinal hernia. The patient reported a swelling in his left lower abdomen over the past 6 months. Magnetic resonance imaging revealed a left inguinal mass extending from the ...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-008-0850-7

    authors: Minagawa T,Matsushita K,Shimada R,Takayama H,Hiraga R,Uehara T,Murata Y

    更新日期:2009-08-01 00:00:00

  • Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.

    abstract::Combination chemotherapy with cisplatin and pemetrexed is the most active first-line regimen for malignant pleural mesothelioma (MPM). However, no drugs have been approved for second-line treatment of MPM, with effective regimens remaining to be identified for patients in relapse. We have now evaluated the combination...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-010-0064-7

    authors: Hayashi H,Okamoto I,Ichikawa Y,Miyazaki M,Yoshioka H,Kunimasa K,Nakagawa K

    更新日期:2010-10-01 00:00:00

  • Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis.

    abstract:BACKGROUND:Early tumor shrinkage (ETS) is a response-related endpoint of clinical trials of chemotherapy (CHT) of patients with metastatic colorectal cancer (mCRC). It identifies a dimensional reduction of tumor size by at least 20-30% after 6-8 weeks of CHT. METHODS:A literature search of randomized trials of systemi...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10147-019-01405-1

    authors: Colloca GA,Venturino A,Guarneri D

    更新日期:2019-03-01 00:00:00

  • The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.

    abstract:BACKGROUND:The activity and synergy for the combination treatment of cisplatin and gemcitabine has been identified in a variety of human tumor cells, including ovarian cancer cells, and has been widely approved for the treatment of non-small cell lung cancer, pancreatic cancer and biliary tract cancer. As the gastroint...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-013-0599-5

    authors: Tomita Y,Saito T,Okadome M,Eto T,Ariyoshi K,Shimamoto K

    更新日期:2014-08-01 00:00:00

  • Cytokine profile in cervical mucosa of Japanese patients with cervical intraepithelial neoplasia.

    abstract:BACKGROUND:Immune responses in the uterine cervix are considered to play an important role in persistent human papillomavirus (HPV) infection and carcinogenesis, but many aspects of the mechanism are still unclear. The goal of this study was to measure cytokines to analyze immune responses in patients with cervical int...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-014-0680-8

    authors: Iwata T,Fujii T,Morii K,Saito M,Sugiyama J,Nishio H,Morisada T,Tanaka K,Yaguchi T,Kawakami Y,Aoki D

    更新日期:2015-02-01 00:00:00

  • Severe gustatory disorder caused by cisplatin and etoposide.

    abstract::A 48-year-old woman with small-cell lung cancer received combined chemotherapy consisting of cisplatin (CDDP) and etoposide (Vp-16). Although the gustatory threshold in the glossopharyngeal nerve area was normal (14 dB) before chemotherapy, it rose to 22 dB on day 8 of chemotherapy, and it could not be measured, becau...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s101470200017

    authors: Minakata Y,Yamagata T,Nakanishi H,Nishimoto T,Nakanishi M,Mune M,Yukawa S

    更新日期:2002-04-01 00:00:00

  • Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.

    abstract:BACKGROUND:Alternative anti-androgen therapy (AAT) with flutamide after combined androgen blockade (CAB) therapy with bicalutamide for metastatic prostate cancer is common. However, no studies have compared enzalutamide without AAT with enzalutamide after AAT with flutamide as treatment for castration-resistant prostat...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-019-01413-1

    authors: Iguchi T,Tamada S,Kato M,Yasuda S,Otoshi T,Hamada K,Yamasaki T,Nakatani T

    更新日期:2019-07-01 00:00:00

  • Immune-resistant mechanisms in cancer immunotherapy.

    abstract::Immune checkpoint inhibitors (ICI) such as PD-1/PD-L1 antibodies (Abs) and CTLA4 Abs and T cell-based adoptive cell therapies are effective for patients with various cancers. However, response rates of ICI monotherapies are still limited due to lack of immunogenic antigens and various immune-resistant mechanisms. The ...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s10147-019-01611-x

    authors: Kawakami Y,Ohta S,Sayem MA,Tsukamoto N,Yaguchi T

    更新日期:2020-05-01 00:00:00

  • Chemotherapy for patients with unresectable or metastatic small bowel adenocarcinoma: a systematic review.

    abstract:BACKGROUND:There is no standard chemotherapy available for unresectable or metastatic small bowel adenocarcinoma (SBA) because of its rarity. This systematic review aims to assess the efficacy and safety of chemotherapy for patients with unresectable or metastatic SBA. METHODS:In accordance with the PRISMA statements,...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-020-01703-z

    authors: Nishikawa Y,Hoshino N,Horimatsu T,Funakoshi T,Hida K,Sakai Y,Muto M,Nakayama T

    更新日期:2020-08-01 00:00:00

  • Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.

    abstract:BACKGROUND:The objective was to evaluate the incidence of second primary malignancies (SPMs) in thyroid cancer patients compared to age- and gender-matched controls without thyroid cancer from the general population of the same region. METHODS:Tampere and Oulu University Hospitals treated 910 patients with well-differ...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-015-0904-6

    authors: Hakala TT,Sand JA,Jukkola A,Huhtala HS,Metso S,Kellokumpu-Lehtinen PL

    更新日期:2016-04-01 00:00:00

  • The role of aromatase inactivators in the treatment of breast cancer.

    abstract::Third-generation aromatase inhibitors and inactivators have earned their place in the treatment of metastatic breast cancer. The third-generation aromatase inactivator exemestane was found to be superior to megestrol acetate as second-line endocrine therapy in postmenopausal women, with respect to time to progression ...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s101470200038

    authors: Lønning PE

    更新日期:2002-08-01 00:00:00

  • Prognostic impact of underlying lung disease in pulmonary wedge resection for lung cancer.

    abstract:BACKGROUND:Pulmonary wedge resection is an option for lung cancer patients with limited cardiopulmonary preservation. As the impact of underlying lung status on the prognosis of such patients remains unclear, we assessed this issue. METHODS:A total of 149 borderline surgical candidates with localized lung cancer who h...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-018-1367-3

    authors: Kawaguchi T,Sawabata N,Miura S,Kawai N,Yasukawa M,Tojo T,Taniguchi S

    更新日期:2019-04-01 00:00:00

  • Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.

    abstract:PURPOSE:The purpose of our study was to evaluate the efficacy of a new combination antiemetic therapy consisting of palonosetron, aprepitant, and dexamethasone in gastric cancer patients undergoing chemotherapy with S-1 plus cisplatin. METHODS:This prospective, multi-institutional observational study assessed patient-...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10147-015-0916-2

    authors: Oyama K,Fushida S,Kaji M,Takeda T,Yabushita K,Nezuka H,Kinami S,Kadoya N,Takai Y,Tsukioka Y,Ohyama S,Tsuji K,Tsukada T,Kinoshita J,Fujimura T,Ohta T

    更新日期:2016-06-01 00:00:00

  • The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer.

    abstract:BACKGROUND:The aim of this study was to investigate the prognostic role of the pretreatment neutrophil-to-lymphocyte ratio (NLR) as a predictive marker prior to treatment of cervical cancer with radiation therapy (RT) alone or concurrent chemoradiation therapy (CCRT). METHODS:Fifty-six patients with squamous cell carc...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-015-0807-6

    authors: Mizunuma M,Yokoyama Y,Futagami M,Aoki M,Takai Y,Mizunuma H

    更新日期:2015-10-01 00:00:00

  • Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer.

    abstract:BACKGROUND:We proposed a novel treatment strategy, consisting of triweekly cisplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy without adjuvant radiation therapy to treat locally advanced cervical cancer. However, cisplatin-related severe non-hematologic toxicities were frequent during thi...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-020-01787-7

    authors: Nagao S,Yamamoto K,Oishi T,Yamaguchi S,Takehara K,Shimada M,Kigawa J

    更新日期:2021-01-01 00:00:00

  • Value of free-to-total prostate-specific antigen ratio for detection and staging of prostate cancer.

    abstract::Background. We aimed to evaluate the clinical usefulness of measurement of the free-to-total (F/T) ratio of prostate-specific antigen (PSA) for the differentiation of prostate cancer from benign prostate hyperplasia (BPH) and for the staging of prostate cancer. Values for PSA density (PSAD) and PSAD adjusted to the tr...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s101470050002

    authors: Furuya Y,Akakura K,Ito H

    更新日期:2000-02-01 00:00:00

  • Combination therapy with PD-1 or PD-L1 inhibitors for cancer.

    abstract::Immune checkpoint inhibitors (ICIs)-such as antibodies to programmed cell death-1 (PD-1), to its ligand PD-L1, or to cytotoxic T lymphocyte-associated protein-4 (CTLA-4)-are an evolving treatment option for several types of cancer, but only a limited number of patients benefit from such therapy. Preclinical studies ha...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s10147-019-01548-1

    authors: Hayashi H,Nakagawa K

    更新日期:2020-05-01 00:00:00